StockNews.com Upgrades Protalix BioTherapeutics (NYSE:PLX) to “Strong-Buy”

Protalix BioTherapeutics (NYSE:PLX) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report released on Wednesday.

Separately, HC Wainwright upped their price objective on shares of Protalix BioTherapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a report on Monday, February 3rd.

Protalix BioTherapeutics Price Performance

Shares of PLX opened at $2.17 on Wednesday. Protalix BioTherapeutics has a 1 year low of $0.82 and a 1 year high of $2.76. The stock’s fifty day moving average price is $2.38 and its two-hundred day moving average price is $1.69. The firm has a market cap of $159.79 million, a PE ratio of -16.69 and a beta of 0.72.

Institutional Investors Weigh In On Protalix BioTherapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC grew its position in shares of Protalix BioTherapeutics by 24.1% in the fourth quarter. Cubist Systematic Strategies LLC now owns 29,307 shares of the company’s stock valued at $55,000 after purchasing an additional 5,686 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its stake in Protalix BioTherapeutics by 13.7% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 53,507 shares of the company’s stock worth $101,000 after purchasing an additional 6,434 shares during the period. Millennium Management LLC grew its holdings in Protalix BioTherapeutics by 3.8% during the 4th quarter. Millennium Management LLC now owns 387,921 shares of the company’s stock valued at $729,000 after buying an additional 14,164 shares in the last quarter. Squarepoint Ops LLC increased its position in shares of Protalix BioTherapeutics by 33.4% during the fourth quarter. Squarepoint Ops LLC now owns 73,940 shares of the company’s stock valued at $139,000 after buying an additional 18,522 shares during the period. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Protalix BioTherapeutics in the fourth quarter worth about $35,000. Institutional investors own 16.53% of the company’s stock.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.